Group One Trading
ACAD icon

Group One Trading’s Acadia Pharmaceuticals ACAD Stock Holding History

Group One Trading’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$127K Buy
5,700
+5,500
+2,750% +$131K ﹤0.01% 4511
2025
Q4 		$5.34K Sell
200
-113,000
-100% -$2.7M ﹤0.01% 7151
2025
Q3 		$2.42M Buy
113,200
+19,300
+21% +$456K ﹤0.01% 2119
2025
Q2 		$2.03M Buy
93,900
+73,000
+349% +$1.36M ﹤0.01% 2133
2025
Q1 		$347K Sell
20,900
-83,400
-80% -$1.52M ﹤0.01% 3453
2024
Q4 		$1.91M Buy
104,300
+62,500
+150% +$1.01M ﹤0.01% 1958
2024
Q3 		$643K Buy
41,800
+11,800
+39% +$197K ﹤0.01% 2673
2024
Q2 		$488K Buy
30,000
+1,500
+5% +$24.2K ﹤0.01% 2587
2024
Q1 		$527K Sell
28,500
-316,200
-92% -$7.83M ﹤0.01% 2673
2023
Q4 		$10.8M Buy
344,700
+50,200
+17% +$1.2M 0.03% 655
2023
Q3 		$6.14M Buy
294,500
+5,700
+2% +$155K 0.02% 806
2023
Q2 		$6.92M Buy
288,800
+16,100
+6% +$358K 0.02% 737
2023
Q1 		$5.13M Sell
272,700
-10,800
-4% -$206K 0.02% 826
2022
Q4 		$4.51M Buy
283,500
+18,000
+7% +$281K 0.01% 1210
2022
Q3 		$4.34M Buy
265,500
+197,700
+292% +$3.2M 0.01% 1273
2022
Q2 		$955K Sell
67,800
-53,500
-44% -$998K ﹤0.01% 2802
2022
Q1 		$2.94M Sell
121,300
-273,400
-69% -$6.62M ﹤0.01% 2012
2021
Q4 		$9.21M Buy
394,700
+335,000
+561% +$6.74M 0.01% 1168
2021
Q3 		$992K Sell
59,700
-52,900
-47% -$1.02M ﹤0.01% 3424
2021
Q2 		$2.75M Buy
112,600
+79,700
+242% +$1.8M ﹤0.01% 2310
2021
Q1 		$849K Sell
32,900
-157,900
-83% -$6.95M ﹤0.01% 3423
2020
Q4 		$10.2M Buy
190,800
+12,100
+7% +$601K 0.02% 799
2020
Q3 		$7.37M Sell
178,700
-12,900
-7% -$557K 0.02% 673
2020
Q2 		$9.29M Buy
191,600
+12,600
+7% +$605K 0.04% 477
2020
Q1 		$7.56M Sell
179,000
-53,500
-23% -$2.2M 0.06% 351
2019
Q4 		$9.95M Buy
232,500
+1,200
+0.5% +$52.2K 0.07% 345
2019
Q3 		$8.32M Buy
231,300
+96,700
+72% +$2.93M 0.07% 347
2019
Q2 		$3.6M Sell
134,600
-148,400
-52% -$3.79M 0.03% 709
2019
Q1 		$7.6M Buy
283,000
+51,300
+22% +$1.2M 0.08% 267
2018
Q4 		$3.75M Sell
231,700
-2,500
-1% -$48.5K 0.03% 644
2018
Q3 		$4.86M Buy
234,200
+34,600
+17% +$544K 0.04% 597
2018
Q2 		$3.05M Buy
199,600
+73,900
+59% +$1.32M 0.03% 826
2018
Q1 		$2.82M Sell
125,700
-89,800
-42% -$2.49M 0.03% 771
2017
Q4 		$6.49M Buy
215,500
+41,800
+24% +$1.34M 0.05% 509
2017
Q3 		$6.54M Sell
173,700
-102,700
-37% -$3.34M 0.06% 407
2017
Q2 		$7.71M Sell
276,400
-26,900
-9% -$802K 0.08% 296
2017
Q1 		$10.4M Sell
303,300
-4,500
-1% -$159K 0.12% 186
2016
Q4 		$8.88M Buy
+307,800
New +$8.14M 0.09% 249
2013
Q3 		– Sell
-667,400
Closed -$12.1M – 5101
2013
Q2 		$12.1M Buy
+667,400
New +$9.19M 0.3% 48

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Group One Trading's ACAD Position: Q1 2026 in Review

Group One Trading reduced its Acadia Pharmaceuticals (ACAD) stake by 67% in Q1 2026, selling an estimated $150K and leaving 3,032 shares worth $67.5K. The position accounts for ﹤0.01% of the portfolio, ranked #5045.

Group One Trading first reported a position in ACAD in Q2 2013 and has held it in 40 quarters since. The position peaked at $13.9M in Q1 2014. 340 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

  • Group One Trading held 3,032 shares of Acadia Pharmaceuticals worth $67.5K as of Q1 2026.
  • Group One Trading sold 6,281 Acadia Pharmaceuticals shares in Q1 2026, an estimated $150K.
  • Acadia Pharmaceuticals made up ﹤0.01% of Group One Trading's portfolio in Q1 2026, its #5045 holding.
  • Group One Trading first reported a position in Acadia Pharmaceuticals in Q2 2013 and has held it in 40 quarters since.
  • Group One Trading's Acadia Pharmaceuticals position peaked at $13.9M in Q1 2014.
  • 340 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.